Inve US ▾

Mineralys Therapeutics (MLYS) earnings

Mineralys Therapeutics, Inc.· Health Care

Results to
Jun 2026
Latest analysed call
Jun 2026 (Q2 FY26)
Balance sheet to
Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Mineralys Therapeutics earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
RevenueUnavailable—Quarterly, as filedQuarter to Jun 2026Not in the filed figures for the quarter to jun 2026. No older figure is substituted.
Operating marginUnavailable—Operating profit / revenueQuarter to Jun 2026Not in the filed figures for the quarter to jun 2026. No older figure is substituted.
Net profit-241 $ million—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$20.92 +3.05% · +$0.62

Last close Oct 19, 2026 · US · USD

Performance −52.0% 1Y

$20.0$30.0$40.0Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Aug 26Oct 26Jun 2026 (Q2 FY26) — 11 Aug 2026

1Y: $43.56 on 17 Oct 2025 → $20.92. High $47.33 (12 Nov 2025), low $20.3 (16 Oct 2026).

Previous close
$20.3
52-week range
$20.3 – $47.33
One year
−52.63%

Overview

Symbol
MLYS
Exchange
US
Currency
USD

Your own record

Start an Inve Case for Mineralys Therapeutics, Inc.

Free account. Everything above stays public.

Write why you follow Mineralys Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other US companies filed under M

All 182 companies under M

US companies A–Z · Earnings calls · US earnings-call directory · US sector analysis · What management promised, and delivered